Why do weight and PCOS affect each other?
PCOS varies widely between women. The 2023 international evidence-based guideline (Teede and colleagues) names insulin resistance as a pathophysiological factor in PCOS. It also points to mechanisms that drive greater weight gain over time and a higher BMI, which can make weight management harder. Routine insulin blood tests are not recommended for care, because the assays are of limited use.
Weight is one thread among several. Excess hair growth is the clearest outward sign of high androgens, and the piece on unwanted facial hair in women explains why it is a hormone question first. Acne or hair thinning on their own are weaker pointers to PCOS, as the article on what a doctor checks first in adult acne describes. The guideline also notes that many women with PCOS meet weight stigma in healthcare, and asks clinicians to be aware of it.
What do lifestyle and metformin do?
The guideline recommends lifestyle intervention for all women with PCOS. It notes that a healthy lifestyle has benefits even without weight loss, and that structured, ongoing lifestyle support appears as effective in PCOS as in the general population. For women with a higher weight, weight management can bring clinical improvement, and the goal is individualised.
For metformin, the guideline says it should be considered in adults with a BMI of 25 or more for weight and metabolic outcomes such as glucose and lipids, and that metformin and active lifestyle intervention have similar efficacy. Digestive effects are common and usually settle, and a low starting dose with slow increases helps. Where the problem is excess hair with irregular cycles, the combined pill is preferred over metformin, and where the aim is metabolic, metformin is preferred over the pill. The guideline rates the overall evidence as low to moderate quality.
What do the trials of GLP-1 medicines in PCOS show?
The guideline recommends anti-obesity medicines in PCOS for reproductive outcomes only in research settings. A systematic review done to inform it found 11 trials, with 545 participants on the medicines and 451 in comparison arms, and described the published data as very limited. Liraglutide and semaglutide appeared better than placebo for weight, and the studies were too different to pool for most comparisons.
The trials since are small. A placebo-controlled trial of liraglutide 3 mg, a daily medicine, randomised 82 women with obesity and PCOS (55 on the medicine, 27 on placebo) for 32 weeks with lifestyle advice. Weight fell 5.7% against 1.4%, the free androgen index fell, and digestive effects occurred in 58.2% against 18.5%. An open-label trial of weekly semaglutide 1 mg with metformin against metformin alone randomised 100 women, 80 of whom completed 16 weeks: weight fell 6.09 kg against 2.25 kg, testosterone and menstrual recovery were better, and more women conceived naturally between weeks 16 and 40, while all were on metformin alone. An open-label trial of weekly tirzepatide 5 mg with metformin against metformin, in 60 women for 16 weeks, reported a fall of 10.4 kg against 1.7 kg, more loss of visceral fat and higher menstrual recovery. These last two trials come from the same group and carry one registry number.
A retrospective UK cohort adds scale without control. Among 54,114 women prescribed tirzepatide for weight, 4,241 had self-reported PCOS, and at 10 months mean weight loss was 19.40% in 40 women with PCOS and 18.74% in 397 without, which did not differ significantly. So the pattern is consistent: weight falls, and in the small trials cycles and androgens move the right way. None of these studies is long, blinded and large, and most follow women only for months. The explainer on tirzepatide covers the general weight trial evidence.
What can they not do?
They are not a fertility treatment. The guideline limits their use for reproductive outcomes to research. The Malaysian Mounjaro label says tirzepatide should be discontinued at least 1 month before a planned pregnancy, and the US Wegovy label says semaglutide at least 2 months before, because of the long half-life of each. The US Zepbound label states that weight loss offers no benefit in pregnancy and advises stopping when pregnancy is recognised. The pregnancies reported in the semaglutide trial happened after the medicine had been stopped.
They do not replace the diagnosis either. PCOS is not an indication on the Malaysian tirzepatide label, whose registered uses for weight are set by BMI, and the first step remains the assessment the guideline describes, with the cycle, androgen and metabolic questions answered before weight is addressed on its own.
How do they interact with contraception?
Combined oral contraceptives are widely used in PCOS for cycle control and for excess hair, which is why this matters. The US Zepbound label says the medicine may reduce the effect of oral hormonal contraceptives by slowing the stomach, most after the first dose, and advises a switch to a non-oral method or an added barrier method for 4 weeks after starting and for 4 weeks after each dose increase. The Malaysian Mounjaro label reports that a single 5 mg dose lowered the peak level of the pill's ethinyl estradiol by 59% and the overall exposure by 20%, judges this not clinically relevant and requires no change to the pill dose. It also recommends that women who can become pregnant use contraception.
The two labels differ in emphasis, so the practical step is to ask the prescriber which advice applies, and to settle the contraceptive plan before the first dose. Digestive side effects such as vomiting and diarrhoea are covered in the article on weight-loss injection side effects.
Who decides, and how are these medicines obtained?
These are prescription-only medicines, used after a full evaluation by a doctor. The piece on what a doctor checks before prescribing lists the questions, and a woman with PCOS adds cycle history, plans for pregnancy and current contraception to them. At this clinic GLP-1 medicines are used only after a full assessment with regular follow-up, within medical weight management. Obtaining them without that review carries its own risks, set out in the article on getting GLP-1 medicines legally in Malaysia.
The honest complication
The evidence is thin where women most want certainty. The trials are small, short and often open-label, and the reproductive results come from a few hundred women at most. Lifestyle and metformin remain the centre of the guideline, and weight can come back when a medicine stops. A GLP-1 medicine is one option a doctor may discuss with a woman who has PCOS and a higher weight, and it belongs in a plan made after the diagnosis.
